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Approximately 6-8% of Swedish and Danish children have asthma, and rhinitis or atopic dermatitis are even more common. 1, 2 Although the previous increase in asthma prevalence seems to have reached a plateau, variation in prevalence between genetically similar populations strongly implies that a substantial proportion is attributable to environmental aspects. 3 In order to study causes and consequences of asthma and allergic disease, it is of great importance to have valid measures of exposures, outcomes and confounders and adequate sample sizes. Many prospective birth cohorts, case-control studies and randomized control trials have ascertained feasible associations from data collected through questionnaires and clinical examinations. In some countries, these have been complemented with populationbased information from medical records collected at antenatal clinics and hospital visits, and to prescribed drugs; all linked through personal identity numbers. Importantly, asthma outcomes have been well ascertained in validation studies through extensive linkages, medical record reviews and algorithms. 4, 5 These register-based total population studies also allow comparison on asthma prevalence and incidence between different countries.
In a recent study by Henriksen et al, incidence rates of atopic dermatitis, asthma and allergic rhinoconjunctivitis in the Danish and Swedish child populations are reported based on data from national registers. 6 Incidence rates were ascertained through algorithms based on disease-specific dispensed prescribed medication and/or specific hospital contacts. Findings were that incidence rate of atopic dermatitis was stable and allergic rhinoconjunctivitis decreased in both countries, whereas the incidence rate of asthma increased until 2006 and stabilized for the rest of the study period in Denmark and increased in Sweden. They also report that at age 5 years, one third of all children were affected with at least one of the conditions.
The study certainly shows that it is possible to assess patterns in prevalence and incidence of asthma and allergic disease through the population-based registers, but a few issues remain to acknowledge and discuss. of outpatient visits to specialists but not those to primary health care. This is why dispensed medication from the Prescribed Drug Registers, which covers all health care facilities, is such an important source. In a recent validation study of asthma and atopic dermatitis, we concluded that asthma medication (≥ two filled prescriptions) is a suitable proxy for asthma with a positive predicted value (PPV) by predefined medication criteria that ranged between 0.75 and 0.94 depending on age group. Meanwhile, medications for atopic dermatitis had a much lower PPV. 4 We based our validation on a large number of medical records which would be a great addition also for this study, but in the meantime we are very satisfied with the opportunity to have alternative measures of atopic dermatitis. Another concern is that many of the drugs to treat atopic dermatitis and rhinoconjunctivitis can be provided over the counter (OTC) in Swedish pharmacies since 1992 and in supermarkets since 2009. Thus, incidence and prevalence of these diseases based on the Prescribed Drug Registers will be underestimated. Also, the authors have assessed rhinoconjunctivitis from birth, whereas it is more common that the disease starts later in preschool age. Hence, while it is a clear advantage to have alternative measures of asthma and allergic disease, ideally OTC sales should be considered when interpreting incidence trends. An increase in the proportion of OTC sales can otherwise be misinterpreted as a decrease in incidence rates.
Secondly, it is worth noting that the study populations were born during different time countries as is done in this study can improve our understanding of the diseases and the interpretation of the data. However, age stratified incidence rate ratio curves would be of great help for further understanding of the incidence development in the two countries.
Finally, the authors claim there has been an increase in asthma incidence in Sweden over time, illustrated with a red line in their Figure 1 . The increase seems to have been there only between 2009 and 2010, and since the incidence is not calculated for later years it is difficult to claim an overall increase. Interestingly, the increase coincides with the swine flu pandemic when Swedish residents were invited to immunize their little children. 7 Also, public health information and surveillance was targeted towards infants and young children whose parents were advised to contact health care in case of respiratory symptoms related to influenza. We also know that the number of health care events and prescribed medication increased during this year which may reflect the increase in asthma diagnoses and medication. In Denmark, immunization was primarily targeted towards risk groups 8 and children in the Danish study population were older at the time of the influenza pandemic, possibly explaining why there is not a similar rise in asthma incidence during those years.
In conclusion, the study is of great interest and illustrates that despite some differences in population characteristics the incidence rates are fairly similar between the two countries. The results reinforce the possibilities to study causes and consequences of these diseases in population-based register linkages. In doing so, sophisticated research methods including family design such as sibling comparison can rule out alternative mechanisms that confound associations between early risks and later disease, including all unmeasured genetic and environmental factors shared by siblings such as we have recently shown for antibiotics 9 and parental age. 10 Some of the authors of this paper also have expertise in twin design, which enables a particularly interesting sibling comparison. Most importantly, this article highlights the importance of using valid measures in register-based research and calls for advanced epidemiological analyses methods now and in the future.
